
繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
10-Q: Q2 2024 Earnings Report
10-Q: Q2 2024 Earnings Report
10-Q:2024財年二季報
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb reported Q2 2024 revenues of $12.2 billion, up 9% year-over-year, driven by strong performance in its Growth Portfolio and Eliquis. Net earnings were $1.68 billion with diluted EPS of $0.83. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.6 billion, while the Legacy Portfolio grew 2% to $6.6 billion.The company completed several strategic acquisitions in 2024, including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, strengthening its pipeline across key therapeutic areas. BMS also entered into a collaboration with SystImmune for co-development of BL-B01D1. To fund these acquisitions, the company issued $13 billion in senior unsecured notes during Q1 2024.Looking ahead, BMS continues to execute on its $1.5 billion cost savings initiative by end of 2025, focusing resources on R&D programs with the highest potential returns. The company received multiple regulatory approvals including Breyanzi for additional indications and Krazati for colorectal cancer. Operating cash flow remained strong at $5.2 billion for the first half of 2024, supporting continued investment in innovation and growth.
Bristol-Myers Squibb reported Q2 2024 revenues of $12.2 billion, up 9% year-over-year, driven by strong performance in its Growth Portfolio and Eliquis. Net earnings were $1.68 billion with diluted EPS of $0.83. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.6 billion, while the Legacy Portfolio grew 2% to $6.6 billion.The company completed several strategic acquisitions in 2024, including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, strengthening its pipeline across key therapeutic areas. BMS also entered into a collaboration with SystImmune for co-development of BL-B01D1. To fund these acquisitions, the company issued $13 billion in senior unsecured notes during Q1 2024.Looking ahead, BMS continues to execute on its $1.5 billion cost savings initiative by end of 2025, focusing resources on R&D programs with the highest potential returns. The company received multiple regulatory approvals including Breyanzi for additional indications and Krazati for colorectal cancer. Operating cash flow remained strong at $5.2 billion for the first half of 2024, supporting continued investment in innovation and growth.
施貴寶報告稱2024年第二季度營業收入爲122億,同比增長9%,主要受到其增長組合和Eliquis強勁表現的驅動。淨收益爲16.8億,攤薄後每股收益爲0.83美元。增長組合,包括Opdivo、Orencia和Yervoy,營業收入增加18%至56億,而傳統組合增長2%至66億。公司在2024年完成了幾項戰略收購,包括Karuna Therapeutics、RayzeBio和Mirati Therapeutics,加強了其在關鍵治療領域的產品線。施貴寶還與SystImmune達成合作,共同開發BL-B01D1。爲了資助這些收購,公司在2024年第一季度發行了130億的高級無擔保票據。展望未來,施貴寶繼續執行其到2025年底節省15億成本的計劃,集中資源於回報潛力最高的研發項目。公司獲得了多個監管批准,包括Breyanzi的額外適應症和Krazati用於結直腸癌。2024年上半年的經營現金流保持強勁,達到52億,支持持續的創新與增長投資。
施貴寶報告稱2024年第二季度營業收入爲122億,同比增長9%,主要受到其增長組合和Eliquis強勁表現的驅動。淨收益爲16.8億,攤薄後每股收益爲0.83美元。增長組合,包括Opdivo、Orencia和Yervoy,營業收入增加18%至56億,而傳統組合增長2%至66億。公司在2024年完成了幾項戰略收購,包括Karuna Therapeutics、RayzeBio和Mirati Therapeutics,加強了其在關鍵治療領域的產品線。施貴寶還與SystImmune達成合作,共同開發BL-B01D1。爲了資助這些收購,公司在2024年第一季度發行了130億的高級無擔保票據。展望未來,施貴寶繼續執行其到2025年底節省15億成本的計劃,集中資源於回報潛力最高的研發項目。公司獲得了多個監管批准,包括Breyanzi的額外適應症和Krazati用於結直腸癌。2024年上半年的經營現金流保持強勁,達到52億,支持持續的創新與增長投資。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
相關股票 相關股票
投資課程

看財報揀好股
快速掌握財報季學習指引
財報季來臨,公司股價最易大升大跌,很多優秀的投資者會將財報季視為“大賺一筆”的好時機。 假設你現在持有某隻股票,該公司發佈財報後股價跳水,大跌10%,此時你會怎麼做? 短期波動不改長期增長邏輯,堅定持有 財報業績不及預期,馬上賣掉止盈止損 未來可能還要跌,賣掉之後反手做空 具體如何選擇?取決於我們是什麼類型的投資者,也
【2025.2】英偉達業績怎麼看?短線股價重點看這個指標
英偉達是近兩年美股中漲勢最好的科技巨頭之一,2024年以來股價更是經歷了顯著的增長,漲幅一度超過了兩倍。這樣的股價表現,首先在一定程度上反映了市場對其AI晶片地位的認可,還有對其前景的期待。 不過在今年1月底,受到DeepSeek低成本AI模型的衝擊,市場擔憂競爭格局發生變化,擔憂AI硬件的投資回報率會受影響,加上整體
【2025.1】特斯拉業績怎麽看?關註這四個重點
又到了美股業績期。而巨頭公司的業績,不但會影響自己的股價,甚至還會影響整個美股市場的走勢,其中也可能蘊含著交易機會。 那麼,這些巨頭公司的業績該怎麼看呢?今天我們聚焦特斯拉,看看特斯拉的業績有哪些關鍵因素,可能會對股價帶來什麼明顯影響…… 1、銷量變化 首先,對新能源車企來說,最重要的觀察指標始終是總交付量, 或者說銷